NCT05870423View on ClinicalTrials.gov

Improving Peptide Receptor Radionuclide Therapy With PARP Inhibitors

PHASE1RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

June 1, 2022

Primary Completion Date

January 1, 2027

Study Completion Date

January 1, 2027

Conditions
Neuroendocrine TumorsPeptide Receptor Radionuclide Therapy
Interventions
DRUG

olaparib

18 days olaparib during each cycle of PRRT

Trial Locations (1)

3000CA

RECRUITING

Erasmus MC, Rotterdam

Sponsors
All Listed Sponsors
lead

Erasmus Medical Center

OTHER